Skip to Main Content

Guadalupe Garcia-Tsao, MD, FRCP

Professor of Medicine (Digestive Diseases)

Contact Information

Guadalupe Garcia-Tsao, MD, FRCP

Mailing Address

  • Yale School of Medicine

    Department of Medicine (Digestive Diseases), P.O. Box 208019

    New Haven, CT 06520-8019

    United States

Research Summary

I am primarily involved in clinical research which focuses on cirrhosis and its complications. This includes the following:

a) diagnosis and staging of cirrhosis, including predictors of decompensation (in compensated cirrhosis) and predictors of death (in decompensated cirrhosis) as well as noninvasive tests in the identification of clinically significant portal hypertension

b) describing the natural history of cirrhosis and its complications but also the effect of etiological therapies on its reversibility

c) pathogenesis and treatment of portal hypertension and investigating the usefulness of portal-pressure reducing drugs and their impact in the prevention of poor outcomes in cirrhosis

d) development of diagnostic criteria and investigation of therapies for ascites and its complications (refractory ascites, acute kidney injury - including hepatorenal syndrome)

e) identification and treatment of infections in cirrhosis, particularly spontaneous bacterial peritonitis

Specialized Terms: Cirrhosis; Natural history of cirrhosis; Portal hypertension, Gastroesophageal varices; Variceal hemorrhage; Ascites; Spontaneous bacterial peritonitis; Hepatorenal syndrome

Coauthors

Research Interests

Ascites; Hepatorenal Syndrome; Liver; Liver Cirrhosis; Liver Diseases; Veterans

Research Image

Selected Publications

  • Concept of Further Decompensation and RecompensationD’Amico G, Garcia-Tsao G. Concept of Further Decompensation and Recompensation 2022, 523-535. DOI: 10.1007/978-3-031-08552-9_47.
  • Preventing Further Decompensation: Consensus Statements of Panel 7Garcia-Tsao G, Reiberger T, Bureau C, D’Amico G, La Mura V, Piano S, Tandon P, Turco L. Preventing Further Decompensation: Consensus Statements of Panel 7 2022, 579-583. DOI: 10.1007/978-3-031-08552-9_51.
  • Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled TrialsHartmann J, Dias J, Pivalizza E, Garcia-Tsao G. Thromboelastography-Guided Therapy Enhances Patient Blood Management in Cirrhotic Patients: A Meta-analysis Based on Randomized Controlled Trials Seminars In Thrombosis And Hemostasis 2022 DOI: 10.1055/s-0042-1757135.
  • FRI516 Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosisNoureddin M, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Harrison S, Garcia-Tsao G, Goodman Z, Chalasani N. FRI516 Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis Journal Of Hepatology 2022, 77: s623-s624. DOI: 10.1016/s0168-8278(22)01564-1.
  • FRI509 Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosisNoureddin M, Tai D, Chng E, Ren Y, Boudes P, Shlevin H, Harrison S, Garcia-Tsao G, Chalasani N, Goodman Z. FRI509 Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis Journal Of Hepatology 2022, 77: s619-s620. DOI: 10.1016/s0168-8278(22)01557-4.
  • SAT496 SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosisO’Leary J, Reddy K, Tandon P, Kamath P, Garcia-Tsao G, Wong F, Lai J, Subramanian R, Thuluvath P, Maliakkal B, Vargas H, Biggins S, Thacker L, Bajaj J. SAT496 SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis Journal Of Hepatology 2022, 77: s887-s888. DOI: 10.1016/s0168-8278(22)02066-9.
  • THU494 Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosisBajaj J, O’Leary J, Tandon P, Garcia-Tsao G, Kamath P, Thuluvath P, Subramanian R, Vargas H, McGeorge S, Fagan A, Wong F, Lai J, Thacker L, Reddy R. THU494 Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis Journal Of Hepatology 2022, 77: s339-s340. DOI: 10.1016/s0168-8278(22)01041-8.
  • Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory AscitesBajaj J, Fischer J, Yeramian P, Gavis E, Fagan A, Angeli P, Garcia-Tsao G, Adams J, Markham P. Safety, Tolerability, Pharmacokinetics, and Efficacy of Terlipressin Delivered by Continuous Intravenous Infusion in Patients with Cirrhosis and Refractory Ascites GastroHep 2022, 2022: 1-8. DOI: 10.1155/2022/5065478.
  • 82: SERUM METABOLITES ON ADMISSION ASSOCIATE WITH OCCURRENCE OF NOSOCOMIAL INFECTIONS IN HOSPITALIZED PATIENTS WITH CIRRHOSISBajaj J, O'Leary J, Tandon P, Garcia-Tsao G, Kamath P, Thuluvath P, Subramanian R, Lai J, Vargas H, Mcgeorge S, Fagan A, Wong F, Thacker L, Reddy K. 82: SERUM METABOLITES ON ADMISSION ASSOCIATE WITH OCCURRENCE OF NOSOCOMIAL INFECTIONS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS Gastroenterology 2022, 162: s-1114. DOI: 10.1016/s0016-5085(22)62677-5.
  • Sa1456: SBP VERSUS NON-SBP BACTERIAL INFECTIONS AT ADMISSION HAVE COMPARABLE OUTCOMES IN A MULTI-CENTER COHORT OF INPATIENTS WITH CIRRHOSISO'Leary J, Reddy K, Tandon P, Kamath P, Garcia-Tsao G, Wong F, Lai J, Subramanian R, Thuluvath P, Maliakkal B, Vargas H, Biggins S, Thacker L, Bajaj J. Sa1456: SBP VERSUS NON-SBP BACTERIAL INFECTIONS AT ADMISSION HAVE COMPARABLE OUTCOMES IN A MULTI-CENTER COHORT OF INPATIENTS WITH CIRRHOSIS Gastroenterology 2022, 162: s-1175-s-1176. DOI: 10.1016/s0016-5085(22)63501-7.
  • 256: PRIOR PERIODONITIS AND PATIENT-REPORTED OUTCOMES PREDICT THE RISK OF 3-MONTH HOSPITALIZATION IN A MULTI-CENTER CIRRHOSIS COHORTBajaj J, Lai J, Tandon P, O'Leary J, Garcia-Tsao G, Wong F, Vargas H, Kamath P, Biggins S, Shaw J, Limon-Miro A, Chew M, Mbachi C, Thacker L, Reddy R. 256: PRIOR PERIODONITIS AND PATIENT-REPORTED OUTCOMES PREDICT THE RISK OF 3-MONTH HOSPITALIZATION IN A MULTI-CENTER CIRRHOSIS COHORT Gastroenterology 2022, 162: s-54. DOI: 10.1016/s0016-5085(22)60136-7.
  • Ascites and its complicationsGarcía‐Tsao G. Ascites and its complications 2022, 2024-2043. DOI: 10.1002/9781119600206.ch98.
  • O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMESRagazzo T, Garcia-Tsao G, Mazo D, Ziteli P, Oliveira C, Singer J, Carrilho F, Pessoa M. O-6 NON-INVASIVE ASSESSMENT OS HEPATIC FIBROSIS BEFORE AND AFTER HCV CURE AND CORRELATION WITH CLINICAL OUTCOMES Annals Of Hepatology 2021, 24: 100493. DOI: 10.1016/j.aohep.2021.100493.
  • 431 SPECIFIC URINARY AND SERUM METABOLITES ON ADMISSION PREDICT THE DEVELOPMENT OF AKI AND NEED FOR DIALYSIS IN HOSPITALIZED PATIENTS WITH CIRRHOSISBajaj J, Garcia-Tsao G, Reddy R, O'Leary J, Vargas H, Lai J, Kamath P, Tandon P, Subramanian R, Thuluvath P, Fagan A, Sehrawat T, De La Rosa-Rodriguez R, Wong F. 431 SPECIFIC URINARY AND SERUM METABOLITES ON ADMISSION PREDICT THE DEVELOPMENT OF AKI AND NEED FOR DIALYSIS IN HOSPITALIZED PATIENTS WITH CIRRHOSIS Gastroenterology 2021, 160: s-775-s-776. DOI: 10.1016/s0016-5085(21)02565-8.
  • THU137 Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosisZanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. THU137 Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis Journal Of Hepatology 2020, 73: s206-s207. DOI: 10.1016/s0168-8278(20)30921-1.
  • AS044 Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney diseaseWong F, Reddy R, Tandon P, O’Leary J, Biggins S, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas H, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. AS044 Stage 1b acute kidney injury in cirrhosis is likely due to underlying chronic kidney disease and would be more appropriately re-classified as acute-on-chronic kidney disease Journal Of Hepatology 2020, 73: s35-s36. DOI: 10.1016/s0168-8278(20)30623-1.
  • SAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trialBajaj J, Yeramian P, Gavis E, Fagan A, Fischer J, Garcia-Tsao G, Angeli P, Smith D, Adams J, Markham P. SAT139 Safety, tolerability, pharmacokinetics and pharmacodynamic activity of terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites: a phase 2a open-label trial Journal Of Hepatology 2020, 73: s718-s719. DOI: 10.1016/s0168-8278(20)31895-x.
  • 1002 ACUTE KIDNEY INJURY IS ASSOCIATED WITH REVERSIBLE PLATELET DYSFUNCTION IN HOSPITALIZED PATIENTS WITH DECOMPENSATED CIRRHOSIS.Zanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. 1002 ACUTE KIDNEY INJURY IS ASSOCIATED WITH REVERSIBLE PLATELET DYSFUNCTION IN HOSPITALIZED PATIENTS WITH DECOMPENSATED CIRRHOSIS. Gastroenterology 2020, 158: s-1301. DOI: 10.1016/s0016-5085(20)33914-7.
  • 458 ARTIFICIAL INTELLIGENCE TECHNIQUES DEMONSTRATE BETTER PREDICTION FOR 90-DAY READMISSION AND DEATH IN WOMEN THAN MEN WITH CIRRHOSIS.Saboo K, Hu C, Reddy K, O'Leary J, Tandon P, Wong F, Garcia-Tsao G, Kamath P, Lai J, Biggins S, Fallon M, Thuluvath P, Subramanian R, Maliakkal B, Vargas H, Thacker L, Iyer R, Bajaj J. 458 ARTIFICIAL INTELLIGENCE TECHNIQUES DEMONSTRATE BETTER PREDICTION FOR 90-DAY READMISSION AND DEATH IN WOMEN THAN MEN WITH CIRRHOSIS. Gastroenterology 2020, 158: s-1279. DOI: 10.1016/s0016-5085(20)33859-2.
  • Su1696 SPLEEN STIFFNESS MEASUREMENTS (SSM) IN THE IDENTIFICATION OF CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN PATIENTS WITH COMPENSATED CIRRHOSIS.Ortiz G, Palumbo C, Sayyar M, Balakrishnan M, Mohanty A, Garcia-Tsao G. Su1696 SPLEEN STIFFNESS MEASUREMENTS (SSM) IN THE IDENTIFICATION OF CLINICALLY-SIGNIFICANT PORTAL HYPERTENSION (CSPH) IN PATIENTS WITH COMPENSATED CIRRHOSIS. Gastroenterology 2020, 158: s-1385. DOI: 10.1016/s0016-5085(20)34131-7.
  • Su1678 IMPACT OF RACE AND ETHNICITY ON OUTCOMES IN A MULTI-CENTER NORTH AMERICAN COHORT OF INPATIENTS WITH CIRRHOSISBajaj J, O'Leary J, Tandon P, Wong F, Garcia-Tsao G, Kamath P, Lai J, Biggins S, Fallon M, Maliakkal B, Subramanian R, Thuluvath P, Vargas H, Thacker L, Reddy K. Su1678 IMPACT OF RACE AND ETHNICITY ON OUTCOMES IN A MULTI-CENTER NORTH AMERICAN COHORT OF INPATIENTS WITH CIRRHOSIS Gastroenterology 2020, 158: s-612. DOI: 10.1016/s0016-5085(20)32229-0.
  • Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosisZanetto A, Rinder H, Deng Y, Ciarleglio M, Wilson F, Bulato C, Simioni P, Garcia-Tsao G. Acute kidney injury is associated with reversible platelet dysfunction in hospitalized patients with decompensated cirrhosis Digestive And Liver Disease 2020, 52: e13. DOI: 10.1016/j.dld.2019.12.031.
  • Gastroesophageal Variceal Bleeding ManagementZanetto A, Garcia-Tsao G. Gastroesophageal Variceal Bleeding Management 2019, 39-66. DOI: 10.1007/978-3-030-24490-3_4.
  • Su1527 – Potentially Preventable Readmissions and Complications in Hospitalized Patients with Hepatic Encephalopathy in a Large Multi-Center CohortBajaj J, Tandon P, O’Leary J, Wong F, Garcia-Tsao G, Biggins S, Kamath P, Thuluvath P, Lai J, Vargas H, Subramanian R, Maliakkal B, Fallon M, Thacker L, Reddy K. Su1527 – Potentially Preventable Readmissions and Complications in Hospitalized Patients with Hepatic Encephalopathy in a Large Multi-Center Cohort Gastroenterology 2019, 156: s-562. DOI: 10.1016/s0016-5085(19)38297-6.
  • 246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic HepatitisLang S, Duan Y, Liu J, Ventura-Cots M, Lucey M, Padilla F, Mathurin P, Louvet A, Garcia-Tsao G, Verna E, Abraldes J, Brown R, Vargas V, Altamirano J, Caballería J, Shawcross D, Ho S, Bataller R, Tu X, Stärkel P, Fouts D, Schnabl B. 246 – Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis Gastroenterology 2019, 156: s-1186. DOI: 10.1016/s0016-5085(19)39939-1.
  • 573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with DecompensationWong F, Reddy K, Tandon P, O'Leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. 573 – Predictive Factors for the Development of Acute-Onchronic Liver Failure in a North American Cohort of Hospitalized Cirrhotic Patients with Decompensation Gastroenterology 2019, 156: s-1205. DOI: 10.1016/s0016-5085(19)39995-0.
  • Sa1570 – Underutilization of Hospice in Inpatients with Cirrhosis: the Nacseld ExperienceO'Leary J, Tandon P, Reddy K, Biggins S, Wong F, Kamath P, Garcia-Tsao G, Maliakkal B, Lai J, Fallon M, Vargas H, Thuluvath P, Subramanian R, Thacker L, Bajaj J. Sa1570 – Underutilization of Hospice in Inpatients with Cirrhosis: the Nacseld Experience Gastroenterology 2019, 156: s-1238. DOI: 10.1016/s0016-5085(19)40093-0.
  • Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and AscitesWong F, Reddy K, Tandon P, O'Leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. Tu1519 – The Natural Histyory of Stages 2 & 3 Acute Kidney Injury (AKI) in Patients with Decompensated Cirrhosis and Ascites Gastroenterology 2019, 156: s-1351. DOI: 10.1016/s0016-5085(19)40399-5.
  • SAT-093-Underutilization of hospice in inpatients with cirrhosis: The NACSELD experienceO’leary J, Reddy R, Tandon P, Biggins S, Wong F, Garcia-Tsao G, Kamath P, Maliakkal B, Lai J, Fallon M, Thuluvath P, Subramanian R, Vargas H, Thacker L, Bajaj J. SAT-093-Underutilization of hospice in inpatients with cirrhosis: The NACSELD experience Journal Of Hepatology 2019, 70: e669. DOI: 10.1016/s0618-8278(19)31333-7.
  • SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohortBajaj J, Tandon P, O’leary J, Wong F, Garcia-Tsao G, Biggins S, Kamath P, Thuluvath P, Lai J, Vargas H, Subramanian R, Maliakkal B, Fallon M, Thacker L, Reddy R. SAT-013-Potentially Preventable readmissions and complications in hospitalized patients with hepatic encephalopathy in a large multi-center cohort Journal Of Hepatology 2019, 70: e630-e631. DOI: 10.1016/s0618-8278(19)31256-3.
  • SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascitesWong F, Reddy R, Tandon P, O’leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. SAT-140-The natural history of stages 2 and 3 acute kidney injury in hospitalized patients with decompensated cirrhosis and ascites Journal Of Hepatology 2019, 70: e692. DOI: 10.1016/s0618-8278(19)31379-9.
  • SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensationWong F, Reddy R, Tandon P, O’leary J, Garcia-Tsao G, Lai J, Vargas H, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. SAT-139-Predictive factors for the development of acute-on-chronic liver failure in a North American cohort of hospitalized patients with cirrhosis and decompensation Journal Of Hepatology 2019, 70: e691-e692. DOI: 10.1016/s0618-8278(19)31378-7.
  • LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertensionGarcia-Tsao G, Bosch J, Kayali Z, Harrison S, Abdelmalek M, Lawitz E, Satapathy S, Ghabril M, Shiffman M, Younes Z, Thuluvath P, Berzigotti A, Albillos A, Robinson J, Chan J, Hagerty D, Sanyal A. LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension Journal Of Hepatology 2019, 70: e127. DOI: 10.1016/s0618-8278(19)30225-7.
  • Esophageal VaricesJakab S, Garcia-Tsao G. Esophageal Varices 2018, 195-208. DOI: 10.1007/978-3-319-98506-0_15.
  • AscitesGarcia‐Tsao G. Ascites 2018, 127-150. DOI: 10.1002/9781119237662.ch9.
  • Tu1542 - Platelet Count Increases after Viral Suppression in Chronic HCV, Independent of Fibrosis StageSayyar M, Saidi M, Zapatka S, Deng Y, Ciarleglio M, Garcia-Tsao G. Tu1542 - Platelet Count Increases after Viral Suppression in Chronic HCV, Independent of Fibrosis Stage Gastroenterology 2018, 154: s-1245-s-1246. DOI: 10.1016/s0016-5085(18)34092-7.
  • Tu1543 - Usefulness of Repeat Liver Stiffness Measurements (LSM) by Transient Elastography (TE) and LSM by Acoustic Radiation Force Impulse (ARFI) in the Clinical Evaluation of Cirrhosis in Patients in whom Initial TE is EquivocalSayyar M, de Oliveira A, Jangouk P, Bernardo A, Garcia-Tsao G. Tu1543 - Usefulness of Repeat Liver Stiffness Measurements (LSM) by Transient Elastography (TE) and LSM by Acoustic Radiation Force Impulse (ARFI) in the Clinical Evaluation of Cirrhosis in Patients in whom Initial TE is Equivocal Gastroenterology 2018, 154: s-1246. DOI: 10.1016/s0016-5085(18)34093-9.
  • 499 - Primary SBP Prophylaxis is Associated with Higher ICU Admission and 30-Day Mortality Compared to Secondary SBP ProphylaxisBajaj J, O'Leary J, Tandon P, Kamath P, Wong F, Garcia-Tsao G, Lai J, Thuluvath P, Subramanian R, Vargas H, Fallon M, Thacker L, Reddy K. 499 - Primary SBP Prophylaxis is Associated with Higher ICU Admission and 30-Day Mortality Compared to Secondary SBP Prophylaxis Gastroenterology 2018, 154: s-1091. DOI: 10.1016/s0016-5085(18)33633-3.
  • GS-015 Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxisBajaj J, Tandon P, O’leary J, Wong F, Biggins S, Garcia-Tsao G, Kamath P, Maliakkal B, Fallon M, Thuluvath P, Lai J, Subramanian R, Vargas H, Thacker L, Reddy R. GS-015 Primary spontaneous bacterial peritonitis prophylaxis is associated with greater ICU admission and 30-day mortality compared to secondary spontaneous bacterial peritonitis prophylaxis Journal Of Hepatology 2018, 68: s66. DOI: 10.1016/s0168-8278(18)30353-2.
  • LBP-019 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASHBosch J, Bureau C, Chalasani N, Lawitz E, Abdelmalek M, Rinella M, Harrison S, Berzigotti A, Sanyal A, Noureddin M, Rockey D, Ber T, Ilan Y, Garcia-Tsao G. LBP-019 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH Journal Of Hepatology 2018, 68: s115. DOI: 10.1016/s0168-8278(18)30446-x.
  • LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertensionChalasani N, Garcia-Tsao G, Goodman Z, Lawitz E, Abdelmalek M, Rinella M, Ryan M, Noureddin M, Jue C, Pyko M, Allgood A, Shlevin H, Horton R, Zomer E, Traber P, Loomba R, Tetri B, Sanyal A, Harrison S. LBO-001 A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension Journal Of Hepatology 2018, 68: s100-s101. DOI: 10.1016/s0168-8278(18)30420-3.
  • Cirrhosis and Portal Hypertension: Staging and PrognosisGarcia-Tsao G. Cirrhosis and Portal Hypertension: Staging and Prognosis 2018, 1-13. DOI: 10.1007/978-3-319-72628-1_1.
  • THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIABrandt E, Haghighat L, Garcia-Tsao G, Henderson K, Pollak J, Proctor D, Young L. THREE TYPES OF INTRAHEPATIC SHUNTS PRESENTING IN A SINGLE PATIENT WITH HEREDITARY HEMORRHAGIC TELANGIECTASIA Journal Of The American College Of Cardiology 2018, 71: a2393. DOI: 10.1016/s0735-1097(18)32934-6.
  • Management of Portal HypertensionGarcia‐Tsao G, Abraldes J. Management of Portal Hypertension 2017, 304-335. DOI: 10.1002/9781119251316.ch12.
  • Reply to Risk Stratification in Acute Variceal BleedingFortune B, Ciarleglio M, Deng Y, Garcia-Tsao G. Reply to Risk Stratification in Acute Variceal Bleeding Journal Of Clinical Gastroenterology 2017, 1. DOI: 10.1097/00004836-900000000-98090.
  • 421 Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic PatientsO'Leary J, Reddy K, Tandon P, Kamath P, Wong F, Garcia-Tsao G, Lai J, Biggins S, Fallon M, Subramanian R, Thuluvath P, Maliakkal B, Thacker L, Bajaj J. 421 Nacseld Acute-on-Chronic Liver Failure (NACSELD-ACLF) Predicts 30-Day Mortality in Admitted Cirrhotic Patients Gastroenterology 2017, 152: s1056-s1057. DOI: 10.1016/s0016-5085(17)33569-2.
  • Tu1549 Albumin Use and Acute Kidney Injury in a Large Real-World Analysis of Cirrhotic InpatientsBajaj J, O'Leary J, Wong F, Garcia-Tsao G, Tandon P, Biggins S, Kamath P, Lai J, Subramanian R, Fallon M, Maliakkal B, Vargas H, Thuluvath P, Thacker L, Reddy K. Tu1549 Albumin Use and Acute Kidney Injury in a Large Real-World Analysis of Cirrhotic Inpatients Gastroenterology 2017, 152: s906. DOI: 10.1016/s0016-5085(17)33097-4.
  • Primary and secondary prophylaxis of esophageal variceal bleedingJangouk P, Garcia-Tsao G. Primary and secondary prophylaxis of esophageal variceal bleeding Techniques And Innovations In Gastrointestinal Endoscopy 2017, 19: 84-89. DOI: 10.1016/j.tgie.2017.03.004.
  • THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammationWinters A, Luedtke S, Moreland A, Jangouk P, Weng G, Silveira M, Davitkov P, Duarte-Rojo A, Cheung R, Garcia-Tsao G, Falck-Ytter Y, Branch A, Bräu N. THU-209 In hepatitis C virus-related advanced fibrosis and cirrhosis, early decline of liver stiffness following antiviral therapy with DAAs is related to decline in liver inflammation Journal Of Hepatology 2017, 66: s280. DOI: 10.1016/s0168-8278(17)30876-0.
  • LBP-523 A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysisTurco L, Villanueva C, La Mura V, Garcia-Pagan J, Reiberger T, Genesca J, Groszmann R, Sharma B, Merkel C, Bureau C, Alvarado E, Abraldes J, Albillos A, Banares R, Peck-Radosavljevic M, Augustin S, Sarin S, Bosch J, Garcia-Tsao G. LBP-523 A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis Journal Of Hepatology 2017, 66: s103-s104. DOI: 10.1016/s0168-8278(17)30468-3.
  • LBP-516 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosisIlan Y, Harrison S, Traber P, Chalasani N, Garcia-Tsao G. LBP-516 13C-Methacetin Breath Test accurately assesses clinically significant portal hypertension in patients with NASH cirrhosis Journal Of Hepatology 2017, 66: s100. DOI: 10.1016/s0168-8278(17)30461-0.
  • FRI-025 Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatientsBajaj J, O’leary J, Wong F, Garcia-Tsao G, Tandon P, Biggins S, Kamath P, Lai J, Fallon M, Subramanian R, Maliakkal B, Thuluvath P, Vargas H, Thacker L, Reddy R, Disease N. FRI-025 Albumin use and acute kidney injury in a large real-world analysis of cirrhotic inpatients Journal Of Hepatology 2017, 66: s378. DOI: 10.1016/s0168-8278(17)31103-0.
  • Chapter 36 AscitesGarcia-Tsao G. Chapter 36 Ascites 2017, 475-484. DOI: 10.1016/b978-0-12-804274-8.00036-9.
  • Su1493 Non-Response to Empirical Treatment for Spontaneous Bacterial Peritonitis (SBP): Incidence, Risk Factors, Clinical Impact, and Antibiotic ChoicesTo U, Delisle A, Garcia-Tsao G. Su1493 Non-Response to Empirical Treatment for Spontaneous Bacterial Peritonitis (SBP): Incidence, Risk Factors, Clinical Impact, and Antibiotic Choices Gastroenterology 2016, 150: s1109-s1110. DOI: 10.1016/s0016-5085(16)33749-0.
  • Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved SurvivalBhutta A, Garcia-Tsao G, Reddy K, Tandon P, Wong F, O'Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. Sa1645 Beta-Blocker (BB) Use in Hospitalized Cirrhotic Patients With Ascites Is Associated With a Lower MELD, Less Inflammation and an Improved Survival Gastroenterology 2016, 150: s1084-s1085. DOI: 10.1016/s0016-5085(16)33659-9.
  • Su1513 In-Hospital Mortality Related to Hepatic Encephalopathy Is Independent of ACLF and Varies Significantly Across North America: NACSELD ExperienceBajaj J, Reddy K, Tandon P, Garcia-Tsao G, Wong F, Kamath P, Biggins S, Fallon M, Maliakkal B, Thuluvath P, Subramanian R, Vargas H, Lai J, Thacker L, O'Leary J. Su1513 In-Hospital Mortality Related to Hepatic Encephalopathy Is Independent of ACLF and Varies Significantly Across North America: NACSELD Experience Gastroenterology 2016, 150: s1117. DOI: 10.1016/s0016-5085(16)33769-6.
  • Tu1649 Predicting Mortality After Discharge From Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky ScoreTandon P, Reddy K, O'Leary J, Garcia-Tsao G, Wong F, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. Tu1649 Predicting Mortality After Discharge From Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score Gastroenterology 2016, 150: s1156. DOI: 10.1016/s0016-5085(16)33906-3.
  • Approach to the Patient with Ascites and Its ComplicationsGarcia‐Tsao G. Approach to the Patient with Ascites and Its Complications 2016, 447-458. DOI: 10.1002/9781118512104.ch55.
  • THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved SurvivalBhutta A, Garcia-Tsao G, Reddy R, Tandon P, Wong F, O’Leary J, Acharya C, Banerjee D, Abraldes J, Plener I, Jones T, Shaw J, Deng Y, Ciarleglio M, Bajaj J. THU-001 Beta-Blocker Use in Hospitalized Cirrhotic Patients with Ascites is Associated with a Lower Meld, less Inflammation and an Improved Survival Journal Of Hepatology 2016, 64: s245. DOI: 10.1016/s0168-8278(16)00253-1.
  • THU-373 Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky ScoreTandon P, Reddy R, O’Leary J, Garcia-Tsao G, Wong F, Biggins S, Maliakkal B, Fallon M, Subramanian R, Thuluvath P, Kamath P, Thacker L, Bajaj J. THU-373 Predicting Mortality after Discharge from Hospital in Cirrhosis: A Prospective Assessment of the Karnofsky Score Journal Of Hepatology 2016, 64: s282. DOI: 10.1016/s0168-8278(16)00340-8.
  • Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of CirrhosisRipoll C, Augustin S, Reiberger T, Moreau R, Salerno F, Albillos A, Abraldes J, Garcia-Tsao G. Effect of Current Therapies Aimed at Preventing Variceal Rebleeding on Other Complications of Cirrhosis 2016, 333-339. DOI: 10.1007/978-3-319-23018-4_33.
  • Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal BleedingAugustin S, Albillos A, Ripoll C, Abraldes J, Salerno F, Moreau R, Reiberger T, Garcia-Tsao G. Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding 2016, 341-353. DOI: 10.1007/978-3-319-23018-4_34.
  • Introduction and Survey ResultsGarcia-Tsao G, Ripoll C, Augustin S, Reiberger T, Albillos A, Moreau R, Salerno F, Abraldes J. Introduction and Survey Results 2016, 303-309. DOI: 10.1007/978-3-319-23018-4_30.
  • Consensus Statements: Preventing Recurrent Variceal Hemorrhage and Other Decompensating EventsAbraldes J, Albillos A, Augustin S, Moreau R, Reiberger T, Ripoll C, Salerno F, Garcia-Tsao G. Consensus Statements: Preventing Recurrent Variceal Hemorrhage and Other Decompensating Events 2016, 365-367. DOI: 10.1007/978-3-319-23018-4_36.
  • Secondary Prophylaxis in Special Patient PopulationsReiberger T, Moreau R, Ripoll C, Albillos A, Augustin S, Salerno F, Abraldes J, Garcia-Tsao G. Secondary Prophylaxis in Special Patient Populations 2016, 317-332. DOI: 10.1007/978-3-319-23018-4_32.
  • Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing CareAlbillos A, Abraldes J, Ripoll C, Reiberger T, Augustin S, Salerno F, Moreau R, Garcia-Tsao G. Prevention of Variceal Rebleeding: Stratifying Risk and Individualizing Care 2016, 311-316. DOI: 10.1007/978-3-319-23018-4_31.
  • THU-347 Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated CirrhosisTurco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Rossi R, Villa E, Schepis F. THU-347 Progressive Alterations in Systemic and Cardiopulmonary Hemodynamics Occur in Patients with Cirrhosis and Predict Death in Decompensated Cirrhosis Journal Of Hepatology 2016, 64: s270-s271. DOI: 10.1016/s0168-8278(16)00314-7.
  • Issues in Trial Design and Areas Needing Further ResearchAbraldes J, Salerno F, Augustin S, Ripoll C, Reiberger T, Moreau R, Albillos A, Garcia-Tsao G. Issues in Trial Design and Areas Needing Further Research 2016, 355-363. DOI: 10.1007/978-3-319-23018-4_35.
  • Ascites and Its ComplicationsGarcia‐Tsao G. Ascites and Its Complications 2015, 2087-2106. DOI: 10.1002/9781118512074.ch106.
  • Corrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974]Angeli P, Ginès P, Wong F, Bernardi M, Boyer T, Gerbes A, Moreau R, Jalan R, Sarin S, Piano S, Moore K, Lee S, Durand F, Salerno F, Caraceni P, Kim W, Arroyo V, Garcia-Tsao G. Corrigendum to “Diagnosis and management of acute kidney injury in patients with cirrhosis: Revised consensus recommendations of the International Club of Ascites” [J Hepatol 2015;62:968–974] Journal Of Hepatology 2015, 63: 290. DOI: 10.1016/j.jhep.2015.04.001.
  • Natural History of CirrhosisGarcia-Tsao G. Natural History of Cirrhosis 2015, 13-20. DOI: 10.1007/978-3-319-13614-1_2.
  • P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patientsBajaj J, Reddy K, Garcia-Tsao G, Wong F, Fallon M, Subramanian R, Biggins S, Maliakkal B, Kamath P, Thuluvath P, Thacker L, O’leary J, behalf of NACSELD. O. P0120 : The 3-month readmission rate remains unacceptably high in a large multi-center cohort of cirrhotic patients Journal Of Hepatology 2015, 62: s345-s346. DOI: 10.1016/s0168-8278(15)30340-8.
  • Mo1892 Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient OutcomesWong F, O'Leary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, Subramanian R, Thuluvath P, Kamath P, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj J. Mo1892 Acute Kidney Injury in Cirrhosis: Baseline Serum Creatinine Predicts Patient Outcomes Gastroenterology 2015, 148: s-1075. DOI: 10.1016/s0016-5085(15)33674-x.
  • 575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic PatientsBajaj J, Reddy K, Garcia-Tsao G, Wong F, Fallon M, Subramanian R, Biggins S, Maliakkal B, Kamath P, Thuluvath P, Thacker L, O'Leary J. 575 The 3-Month Readmission Rate Remains Unacceptably High in a Large Multi-Center Cohort of Cirrhotic Patients Gastroenterology 2015, 148: s-982-s-983. DOI: 10.1016/s0016-5085(15)33360-6.
  • P0119 : Validation Of The NACSELD Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) score in an independent multicenter cohortO’Leary J, Reddy K, Garcia-Tsao G, Biggins S, Wong F, Fallon M, Subramanian R, Kamath P, Thuluvath P, Maliakkal B, Patton H, Tandon P, Thacker L, Bajaj J, behalf of NACSESLD. O. P0119 : Validation Of The NACSELD Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) score in an independent multicenter cohort Journal Of Hepatology 2015, 62: s345. DOI: 10.1016/s0168-8278(15)30339-1.
  • 591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic PatientsO'Leary J, Reddy K, Garcia-Tsao G, Biggins S, Wong F, Fallon M, Subramanian R, Kamath P, Thuluvath P, Maliakkal B, Patton H, Tandon P, Thacker L, Bajaj J. 591 Validation of Infection-Related Acute-on-Chronic Liver Failure (I-ACLF) Definition for 30-Day Mortality Prediction in Infected and Uninfected Hospitalized Cirrhotic Patients Gastroenterology 2015, 148: s-988. DOI: 10.1016/s0016-5085(15)33376-x.
  • O072 : Statin use significantly decreases decompensation and death in veterans with hepatitis C-related compensated cirrhosisMohanty A, Tate J, Garcia-Tsao G. O072 : Statin use significantly decreases decompensation and death in veterans with hepatitis C-related compensated cirrhosis Journal Of Hepatology 2015, 62: s226-s227. DOI: 10.1016/s0168-8278(15)30086-6.
  • P0199 : Acute kidney injury in cirrhosis: Baseline serum creatinine predicts patient outcomesWong F, O’Leary J, Reddy K, Garcia-Tsao G, Fallon M, Biggins S, Subramanian R, Thuluvath P, Kamath P, Patton H, Maliakkal B, Tandon P, Vargas H, Thacker L, Bajaj J, Disease N. P0199 : Acute kidney injury in cirrhosis: Baseline serum creatinine predicts patient outcomes Journal Of Hepatology 2015, 62: s380. DOI: 10.1016/s0168-8278(15)30418-9.
  • Prognostic Factors in Compensated and Decompensated CirrhosisRipoll C, Zipprich A, Garcia-Tsao G. Prognostic Factors in Compensated and Decompensated Cirrhosis Current Hepatology Reports 2014, 13: 171-179. DOI: 10.1007/s11901-014-0234-6.
  • Sa1004 Measurement of Liver and Spleen Stiffness by ARFI Elastography: Intra-and Inter-Observer Variability and Predictors of VariabilityBalakrishnan M, Souza F, Munoz C, Augustin S, Loo N, Deng Y, Ciarleglio M, Garcia-Tsao G. Sa1004 Measurement of Liver and Spleen Stiffness by ARFI Elastography: Intra-and Inter-Observer Variability and Predictors of Variability Gastroenterology 2014, 146: s-934. DOI: 10.1016/s0016-5085(14)63395-3.
  • Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic FactorsSanchez M, Augustin S, Balakrishnan M, Re V, Tate J, Garcia-Tsao G. Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic Factors Gastroenterology 2014, 146: s-974-s-975. DOI: 10.1016/s0016-5085(14)63541-1.
  • Mo1027 Differences in Creatinine Between Genders Could Disadvantage Infected Cirrhotic Women: The Nacseld ExperienceO'Leary J, Wong F, Kamath P, Reddy K, Patton H, Biggins S, Fallon M, Garcia-Tsao G, Subramanian R, Maliakkal B, Malik R, Thacker L, Bajaj J. Mo1027 Differences in Creatinine Between Genders Could Disadvantage Infected Cirrhotic Women: The Nacseld Experience Gastroenterology 2014, 146: s-989. DOI: 10.1016/s0016-5085(14)63596-4.
  • P1013 MEASUREMENT OF LIVER AND SPLEEN STIFFNESS BY ARFI ELASTOGRAPHY: INTRA- AND INTER-OBSERVER VARIABILITY AND PREDICTORS OF VARIABILITYBalakrishnan M, Souza F, Munoz C, Augustin S, Loo N, Deng Y, Ciarleglio M, Garcia-Tsao G. P1013 MEASUREMENT OF LIVER AND SPLEEN STIFFNESS BY ARFI ELASTOGRAPHY: INTRA- AND INTER-OBSERVER VARIABILITY AND PREDICTORS OF VARIABILITY Journal Of Hepatology 2014, 60: s412-s413. DOI: 10.1016/s0168-8278(14)61173-9.
  • P502 SPONTANEOUS BACTERIAL PERITONITIS AND BACTEREMIA PREDICT MORTALITY IN CIRRHOSIS DESPITE PROPHYLACTIC MEASURES: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELDBiggins S, O'Leary J, Reddy K, Wong F, Kamath P, Patton H, Fallon M, Garcia-Tsao G, Subramanian R, Thuluvath P, Maliakkal B, Koch D, Malik R, Thacker L, Bajaj J. P502 SPONTANEOUS BACTERIAL PERITONITIS AND BACTEREMIA PREDICT MORTALITY IN CIRRHOSIS DESPITE PROPHYLACTIC MEASURES: A PROSPECTIVE MULTI-CENTER STUDY FROM NACSELD Journal Of Hepatology 2014, 60: s237. DOI: 10.1016/s0168-8278(14)60664-4.
  • P943 DIFFERENCES IN CREATININE BETWEEN GENDERS COULD DISADVANTAGE INFECTED CIRRHOTIC WOMEN: THE NACSELD EXPERIENCEBajaj J, O'Leary J, Reddy K, Wong F, Fallon M, Biggins S, Patton H, Maliakkal B, Thuluvath P, Garcia-Tsao G, Koch D, Thacker L, Kamath P. P943 DIFFERENCES IN CREATININE BETWEEN GENDERS COULD DISADVANTAGE INFECTED CIRRHOTIC WOMEN: THE NACSELD EXPERIENCE Journal Of Hepatology 2014, 60: s389-s390. DOI: 10.1016/s0168-8278(14)61104-1.
  • Serum B-type natriuretic peptide is more accurate than ascites analyses in the diagnosis of ascites related to heart failureFarias A, Silvestre O, Bacal F, Garcia-Tsao G, Seguro L, Mazo D, Andrade J, Furtado M, Carrilho F, D'Albuquerque L. Serum B-type natriuretic peptide is more accurate than ascites analyses in the diagnosis of ascites related to heart failure European Heart Journal 2013, 34: p4241-p4241. DOI: 10.1093/eurheartj/eht309.p4241.
  • Tu2048 Histological Features Using Quantitative Morphometric Digital Image Analysis Can Predict Hpvg and Help in Sub-Classification of CirrhosisAlduaij A, Jain D, Lesniak A, Demetris A, Garcia-Tsao G, Scott R. Tu2048 Histological Features Using Quantitative Morphometric Digital Image Analysis Can Predict Hpvg and Help in Sub-Classification of Cirrhosis Gastroenterology 2013, 144: s-912. DOI: 10.1016/s0016-5085(13)63404-6.
  • Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education ClassBari K, Augustin S, Eggers C, Hashem H, Desai M, Shea M, Wongcharatrawee S, Lim J, Garcia-Tsao G. Sa1091 Hepatitis C (HCV) Antiviral Therapy is Feasible in Patients With Active Substance use (SU) and Mental Illness (MI) and is More Likely to Occur in Those Who Receive Education Class Gastroenterology 2012, 142: s-967. DOI: 10.1016/s0016-5085(12)63744-5.
  • Spontaneous bacterial peritonitisGarcia‐Tsao G. Spontaneous bacterial peritonitis 2012, 745-750. DOI: 10.1002/9781118321386.ch100.
  • ParacentesisDe Gottardi A, Yeo C, Garcia‐Tsao G. Paracentesis 2012, 1158-1162. DOI: 10.1002/9781118321386.ch154.
  • Functional Gastrointestinal DiseaseHawkey C, Bosch J, Richter J, Garcia‐Tsao G, Chan F. Functional Gastrointestinal Disease 2012, 54-60. DOI: 10.1002/9781118321386.ch10.
  • AscitesGarcia‐Tsao G. Ascites 2012, 103-106. DOI: 10.1002/9781118321386.ch17.
  • In Memoriam: Harold O. Conn, M.D.Boyer J, Garcia‐Tsao G, Groszmann R. In Memoriam: Harold O. Conn, M.D. Hepatology 2012, 55: 658-658. DOI: 10.1002/hep.25550.
  • The presence of esophageal varices (EV), but not treatment with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascitesZipprich A, Garcia-Tsao G, Seufferlein T, Dollinger M. The presence of esophageal varices (EV), but not treatment with beta-blockers, is associated with a poorer survival in patients with cirrhosis and ascites Zeitschrift Für Gastroenterologie 2012, 50 DOI: 10.1055/s-0031-1295840.
  • Chapter 18 AscitesGarcia-Tsao G. Chapter 18 Ascites 2012, 283-295. DOI: 10.1016/b978-1-4377-0881-3.00018-8.
  • 156 Cirrhosis and Its SequelaeGarcia-Tsao G. 156 Cirrhosis and Its Sequelae 2012, 999-1007. DOI: 10.1016/b978-1-4377-1604-7.00156-1.
  • AscitesGarcia‐Tsao G. Ascites 2011, 210-233. DOI: 10.1002/9781444341294.ch10.
  • Congenital Hepatic Vascular MalformationsGarcia-Tsao G. Congenital Hepatic Vascular Malformations 2011, 213-227. DOI: 10.1007/978-1-4419-8327-5_14.
  • Management: Cirrhotic Portal HypertensionLim J, Garcia-Tsao G. Management: Cirrhotic Portal Hypertension 2011, 165-181. DOI: 10.1007/978-1-4419-8327-5_11.
  • Spontaneous Bacterial Peritonitis – Prophylaxis and TreatmentWiest R, Garcia-Tsao G. Spontaneous Bacterial Peritonitis – Prophylaxis and Treatment 2011, 28: 65-82. DOI: 10.1159/000318963.
  • Vasoconstrictor Therapy for Hepatorenal SyndromeYeo C, Garcia-Tsao G. Vasoconstrictor Therapy for Hepatorenal Syndrome 2011, 28: 149-162. DOI: 10.1159/000318997.
  • Classification of Cirrhosis: The Clinical Use of HVPG MeasurementsAlbilllos A, Garcia-Tsao G. Classification of Cirrhosis: The Clinical Use of HVPG Measurements Disease Markers 2011, 31: 121-128. DOI: 10.1155/2011/706032.
  • Hepatic Venous Pressure Gradient, Biopsy or Both?Garcia‐Tsao G. Hepatic Venous Pressure Gradient, Biopsy or Both? 2010, 7-17. DOI: 10.1002/9781444393989.ch1.
  • Antibiotic Prophylaxis and Management of Bacterial InfectionsLim J, Tandon P, Garcia-Tsao G. Antibiotic Prophylaxis and Management of Bacterial Infections 2010, 395-410. DOI: 10.1007/978-1-60761-866-9_20.
  • S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in CirrhosisQamar A, Grace N, Groszmann R, Garcia-Tsao G, Bosch J, Burroughs A, Iskandar H, Maurer R, Planas R, Escorsell A, Garcia-Pagan J, Patch D, Matloff D, Makuch R, From P. S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in Cirrhosis Gastroenterology 2010, 138: s-817. DOI: 10.1016/s0016-5085(10)63764-x.
  • Reply to Qi et al.Garcia-Tsao G. Reply to Qi et al. The American Journal Of Gastroenterology 2010, 105: 472. DOI: 10.1038/ajg.2009.628.
  • Approach to the Patient with Ascites and its ComplicationsGarcia‐Tsao G. Approach to the Patient with Ascites and its Complications 2009, 103-113. DOI: 10.1002/9781444303414.ch10.
  • Ascites and its ComplicationsGarcia‐Tsao G. Ascites and its Complications 2008, 2302-2326. DOI: 10.1002/9781444303254.ch90.
  • Approach to the Patient with Ascites and Its ComplicationsGarcia‐Tsao G. Approach to the Patient with Ascites and Its Complications 2008, 442-466. DOI: 10.1002/9781444300758.ch23.
  • ReplyRipoll C, Garcia–Tsao G, Groszmann R. Reply Gastroenterology 2008, 134: 641-642. DOI: 10.1053/j.gastro.2007.12.006.
  • 317 PROGNOSTIC INDICATORS OF SURVIVAL IN COMPENSATED AND DECOMPENSATED STAGES OF LIVER CIRRHOSIS: VALIDATION OF A 4-STAGE CLASSIFICATIONZipprich A, Dollinger M, Garcia-Tsao G, Rogowski S, Fleig W. 317 PROGNOSTIC INDICATORS OF SURVIVAL IN COMPENSATED AND DECOMPENSATED STAGES OF LIVER CIRRHOSIS: VALIDATION OF A 4-STAGE CLASSIFICATION Journal Of Hepatology 2008, 48: s125-s126. DOI: 10.1016/s0168-8278(08)60319-0.
  • Congenital Vascular MalformationsGarcía‐Tsao G. Congenital Vascular Malformations 2007, 1418-1423. DOI: 10.1002/9780470691861.ch17d.
  • ReplyGroszmann R, Garcia-Tsao G. Reply Gastroenterology 2006, 131: 676. DOI: 10.1053/j.gastro.2006.06.054.
  • Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Internal Medicine 2006, 5: 399-407. DOI: 10.1097/01.mog.0000218962.93806.9a.
  • Session 2: Predictive Models in Portal HypertensionGarcia‐Tsao G, D'Amico G, Abraldes J, Schepis F, Merli M, Kim W, Christensen E. Session 2: Predictive Models in Portal Hypertension 2006, 47-102. DOI: 10.1002/9780470988831.ch4.
  • Chapter 19 AscitesGarcia-Tsao G. Chapter 19 Ascites 2006, 333-346. DOI: 10.1016/b978-1-4160-3258-8.50024-3.
  • Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in CirrhosisGarcia‐Tsao G. Transjugular Intrahepatic Portosystemic Shunt (Tips) for the Management of Refractory Ascites in Cirrhosis 2005, 251-259. DOI: 10.1002/9780470987476.ch20.
  • AscitesKbalid S, Garcia-Tsao G. Ascites 2005, 285-299. DOI: 10.1007/978-1-59259-885-4_19.
  • Treatment of acute variceal bleeding: general management and prevention of infectionsGarcia-Tsao G. Treatment of acute variceal bleeding: general management and prevention of infections 2004, 233-240. DOI: 10.1007/978-94-007-1042-9_25.
  • Comparison of hepatitis C (HCV) treatment patterns in patients with and without mental illness (MI) and/or substance abuse (SA)Chainuvati S, Khalid S, Kancir S, Shea M, Edwards J, Semyak M, Wongcharatrawee S, Garcia-Tsao G. Comparison of hepatitis C (HCV) treatment patterns in patients with and without mental illness (MI) and/or substance abuse (SA) Gastroenterology 2003, 124: a781. DOI: 10.1016/s0016-5085(03)83945-8.
  • 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factorGroszmann R, Garcia-Tsao G, Makuch R, Bosch J, Escorsel A, Garcia-Pagan J, Grace N, Matloff D, Burroughs A, Patch D. 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor Hepatology 2003, 38: 206. DOI: 10.1016/s0270-9139(03)80146-5.
  • 553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis?Nagula S, Jain D, Groszmann R, Garcia-Tsao G. 553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis? Hepatology 2003, 38: 426-427. DOI: 10.1016/s0270-9139(03)80595-5.
  • 1127 Do over-the-counter analgesics contribute to decompensation of cirrhosis? — a prospective studyKhalid S, Addesa J, Navarro V, Garcia-Tsao G. 1127 Do over-the-counter analgesics contribute to decompensation of cirrhosis? — a prospective study Hepatology 2003, 38: 698-699. DOI: 10.1016/s0270-9139(03)81165-5.
  • Session 1 ‒ Definition of Key Events: Lets's Try AgainBurroughs A, Bosch J, Garcia‐Tsao G, Henderson J, Laine L, Nevens F, Riggio O. Session 1 ‒ Definition of Key Events: Lets's Try Again 2001, 13-21. DOI: 10.1002/9780470760154.ch2.
  • Session 2 ‒ Diagnosis of Portal Hypertension: How and WhenD'Amico G, Garcia‐Tsao G, Cales P, Escorsell A, Nevens F, Cestari R, Caletti G, Zoli M. Session 2 ‒ Diagnosis of Portal Hypertension: How and When 2001, 36-64. DOI: 10.1002/9780470760154.ch4.
  • Session 8 ‒ Complications in the Medical Treatment of Portal HypertensionBolognesi M, Balducci G, Garcia‐Tsao G, Gatta A, Gines P, Merli M, Rodes J, Stiegmann G. Session 8 ‒ Complications in the Medical Treatment of Portal Hypertension 2001, 180-203. DOI: 10.1002/9780470760154.ch12.
  • Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 1998, 14: 256-264. DOI: 10.1097/00001574-199805000-00012.
  • Portal hypertensionGarcia-Tsao G. Portal hypertension Current Opinion In Gastroenterology 1997, 13: 263-270. DOI: 10.1097/00001574-199705000-00013.
  • Portal hypertensionGarcia-Tsao, G. Portal hypertension. Curr Opinion Gastro 13:263-270, 1997.
  • A randomized double-blind, placebo-controlled trial ursodeoxycholic acid in primary biliary cirrhosisCombes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized double-blind, placebo-controlled trial ursodeoxycholic acid in primary biliary cirrhosis European Journal Of Gastroenterology & Hepatology 1995, 7: 1132. DOI: 10.1097/00042737-199511000-00024.
  • A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosisCombes B, Carithers R, Maddrey W, Lin D, Mcdonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 1995, 22: 759-766. DOI: 10.1016/0270-9139(95)90294-5.
  • Detection of hepatitis C virus RNA by RT-PCR in the bile of patients with hepatitis CKuan S, Emanuel J, Howe C, West A, Garcia-Tsao G. Detection of hepatitis C virus RNA by RT-PCR in the bile of patients with hepatitis C Gastroenterology 1995, 108: a1103. DOI: 10.1016/0016-5085(95)28715-9.
  • Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-doppler studyBuonamico P, Sabba C, Garcia-Tsao G, Berardi E, Antonica G, Ferraioli G, Jensen J, Lerner E, Taylor K, Albano O, Groszmann R. Octreotide blunts postprandial splanchnic hyperemia in cirrhotic patients: A double-blind randomized echo-doppler study Hepatology 1995, 21: 134-139. DOI: 10.1016/0270-9139(95)90420-4.
  • ReplyGroszmann R, Garcia-Tsao G, Grace N, Bosch J. Reply Gastroenterology 1991, 101: 1760-1761. DOI: 10.1016/0016-5085(91)90443-o.
  • ReplyGroszmann R, Lerner E, Bosch J, Garcia-Tsao G, Grace N. Reply Gastroenterology 1991, 101: 591-592. DOI: 10.1016/0016-5085(91)90052-m.